UpCard-CA1 (torsemide) Oral Solution for Dogs - 2mg/ml
- Size:
- 96 Fl Oz
About this item
Intended For: Dogs
Pet Weight: All
Includes: 32ml, 96ml
Health Considerations: Adverse Reactions: In a multi-site European clinical field study, 251 client-owned dogs suffering from edema secondary to congestive heart failure were treated with at least one dose of a tablet formulation of torsemide (n=126) or furosemide (n=125) for a 3-month treatment period. A greater overall frequency of adverse reactions was recorded in the torsemide group (n=184 events) compared with furosemide treated dogs (n=104 events). The most common adverse reactions associated with torsemide administration involved the urinary system, including polyuria and polydipsia, renal insufficiency, increased BUN and serum creatinine, and urinary incontinence. These findings were noted at greater frequency in torsemide-treated dogs than in the furosemide treatment group. A relative increase in the risk of serious adverse events due to renal insufficiency (including increased BUN, increased serum creatinine, and renal failure) was observed among torsemide-treated dogs compared with furosemide—treated dogs. Median BUN and serum creatinine levels were greater across all time points in torsemide—treated dogs, and were still high in this group on day 84. Electrolyte disturbances, including hypokalemia, hypochloremia, hypercalcemia, and hypomagnesemia, were also associated with torsemide therapy. Diarrhea, vomiting, inappetence, and lethargy were also noted in torsemide-treated dogs. Clinical findings associated with the worsening of congestive heart failure were noted in torsemide-treated dogs, including cough, dyspnea, pulmonary edema, and cardiac arrest. A total of 30 dogs died during the study, 12 in the torsemide group and 18 in the furosemide group. Euthanasia was the most common cause of death with similar frequency between the treatment groups, and was due to progression of renal failure, deterioration of condition, acute pulmonary edema, acute cardiac death, accidental death, death from another disease condition, or unknown cause.
Ingredients: Torsemide 2mg⁄ml
Use: Helps manage pulmonary edema in dogs with congestive heart failure caused by myxomatous mitral valve disease (MMVD). Torsemide has a chemical structure different than furosemide
- leading to a longer half-life, higher bioavailability, and greater potency and duration of diuretic action as compared to furosemide. In a study, torsemide achieved higher owner compliance because of its once daily dosing. The oral solution allows UpCard-CA1 to be easily titrated for specific dosing.
From the manufacturer
